JP7699831B2 - 神経炎症の抑制、そのための組成物及び方法 - Google Patents

神経炎症の抑制、そのための組成物及び方法 Download PDF

Info

Publication number
JP7699831B2
JP7699831B2 JP2022512664A JP2022512664A JP7699831B2 JP 7699831 B2 JP7699831 B2 JP 7699831B2 JP 2022512664 A JP2022512664 A JP 2022512664A JP 2022512664 A JP2022512664 A JP 2022512664A JP 7699831 B2 JP7699831 B2 JP 7699831B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cells
disease
compound
present disclosure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022512664A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021201171A1 (https=
JPWO2021201171A5 (https=
Inventor
正敏 萩原
亜希子 小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University NUC
Original Assignee
Kyoto University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University NUC filed Critical Kyoto University NUC
Publication of JPWO2021201171A1 publication Critical patent/JPWO2021201171A1/ja
Publication of JPWO2021201171A5 publication Critical patent/JPWO2021201171A5/ja
Application granted granted Critical
Publication of JP7699831B2 publication Critical patent/JP7699831B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022512664A 2020-04-01 2021-03-31 神経炎症の抑制、そのための組成物及び方法 Active JP7699831B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020066150 2020-04-01
JP2020066150 2020-04-01
PCT/JP2021/014030 WO2021201171A1 (ja) 2020-04-01 2021-03-31 神経炎症の抑制、そのための組成物及び方法

Publications (3)

Publication Number Publication Date
JPWO2021201171A1 JPWO2021201171A1 (https=) 2021-10-07
JPWO2021201171A5 JPWO2021201171A5 (https=) 2022-12-20
JP7699831B2 true JP7699831B2 (ja) 2025-06-30

Family

ID=77929171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022512664A Active JP7699831B2 (ja) 2020-04-01 2021-03-31 神経炎症の抑制、そのための組成物及び方法

Country Status (5)

Country Link
US (1) US12605368B2 (https=)
EP (1) EP4129340B1 (https=)
JP (1) JP7699831B2 (https=)
CN (1) CN115361973A (https=)
WO (1) WO2021201171A1 (https=)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015083750A1 (ja) 2013-12-05 2015-06-11 国立大学法人京都大学 神経新生に関する化合物及び医薬組成物
WO2018043674A1 (ja) 2016-08-31 2018-03-08 国立大学法人京都大学 神経新生を活性化するための組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9745323B2 (en) 2012-07-30 2017-08-29 Kyoto University Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor
CA2912345C (en) 2013-05-16 2020-10-06 Sumitomo Dainippon Pharma Co., Ltd. Transplantation adjuvant in cell therapy using neural progenitor cells
WO2015107945A1 (ja) 2014-01-17 2015-07-23 ソニー株式会社 スイッチ素子および記憶装置
CN106535890A (zh) 2014-03-20 2017-03-22 萨穆梅德有限公司 5‑取代的吲唑‑3‑羧酰胺及其制备和应用
WO2018029793A1 (ja) 2016-08-09 2018-02-15 株式会社Ａｏｂ慧央グループ Ｉｌ－６産生抑制剤、抗炎症剤、抗神経変性疾患剤、抗精神神経疾患剤、医薬品及び食品
US10604514B2 (en) 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015083750A1 (ja) 2013-12-05 2015-06-11 国立大学法人京都大学 神経新生に関する化合物及び医薬組成物
WO2018043674A1 (ja) 2016-08-31 2018-03-08 国立大学法人京都大学 神経新生を活性化するための組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Acta Neuropathologica Communications，2019年，Vol.7, Article No.46，pp.1-15
MELCHIOR,Benoit et al.，ANTI-INFLAMMATORY EFFECTS OF SM07883, A NOVEL, POTENT, AND SELECTIVE ORAL DYRK1A INHIBITOR IN NEUROD，Alzheimaer's and Dementia，2019年，Vol.15,No.7，Suppl.p.P216
WOO,Hanwoong et al.，The novel DYRK1A inhibitor KD03 alters neuroinflammation in BV2 microglial cells,wild-type, and Alzh，IBRO reports，2019年，Vol.6，p.S130
日本臨床，2003年，Vol.61, No.3，pp.463-468
日本臨床，2014年，Vol.72, Suppl.5，pp.453-458

Also Published As

Publication number Publication date
JPWO2021201171A1 (https=) 2021-10-07
US20230117374A1 (en) 2023-04-20
EP4129340A1 (en) 2023-02-08
EP4129340A4 (en) 2024-08-07
US12605368B2 (en) 2026-04-21
EP4129340B1 (en) 2025-12-03
CN115361973A (zh) 2022-11-18
WO2021201171A1 (ja) 2021-10-07

Similar Documents

Publication Publication Date Title
Xu et al. Prevention of β-amyloid induced toxicity in human iPS cell-derived neurons by inhibition of Cyclin-dependent kinases and associated cell cycle events
JP6663509B2 (ja) 神経幹細胞の分化促進用及び保護用の組成物、並びにそれを利用して神経再生を誘導する方法
JP7285599B2 (ja) 筋萎縮性側索硬化症治療剤及び治療用組成物
JP2015107945A (ja) 神経新生に関する化合物及び医薬組成物
CN103857400B (zh) 玫瑰红景天提取物和分离的化合物及其在治疗神经变性疾病中的应用
CN113439120B (zh) 用于将神经干细胞分化为星形胶质细胞的基于直接细胞转化的方法
JP7699831B2 (ja) 神経炎症の抑制、そのための組成物及び方法
WO2016035934A1 (ko) Gm1 강글리오시드증의 인간 세포 모델 및 이의 용도
CN110869015B (zh) 用于治疗神经炎性紊乱的有机小分子
KR20220000913A (ko) 체세포로부터 분화된 신규한 유사신경교세포 및 이를 포함하는 신경 질환 치료용 세포 치료제
KR101862548B1 (ko) 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법
US12605358B2 (en) Composition for preventing or treating nervous system diseases comprising compound that inhibits mTOR signaling pathway as active ingredient
KR101948247B1 (ko) Oct4 저해용 조성물 및 이의 용도
KR101833412B1 (ko) 신경줄기세포로부터 도파민 신경세포로의 분화 유도용 조성물 및 이를 이용하여 신경줄기세포로부터 도파민 신경세포로 분화시키는 방법
US20210145838A1 (en) Selective pde4d inhibitors against demyelinating diseases
KR20260032533A (ko) 세포 재프로그래밍
HK1262420A1 (en) Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition
HK1262420B (en) Composition for inducing differentiation and protection of neural stem cells and method for inducing neuro-regeneration using the same composition
EA038404B1 (ru) Применение траметиниба для лечения нейродегенеративного заболевания, вызванного утратой или повреждением нейронов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250423

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250605

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250611

R150 Certificate of patent or registration of utility model

Ref document number: 7699831

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150